• 1

    World Health Organization, 1997. Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and Control. Second edition. Geneva: World Health Organization.

  • 2

    Hotta S, 2000. Dengue fever and dengue virus—a challenge to tropical medicine. Jpn J Trop Med Hyg 28 :369–381.

  • 3

    Yamada KI, Takasaki T, Nawa M, Nakayama M, Arai YT, Yabe S, Kurane I, 1999. The features of imported dengue fever cases from 1996 to 1999. Jpn J Infect Dis 52 :257–259.

    • Search Google Scholar
    • Export Citation
  • 4

    Kurane I, Takasaki T, Yamada K, 2000. Trends in flavivirus infections in Japan. Emerg Infect Dis 6 :569–571.

  • 5

    Judicial System Department, Ministers Secretariat, 2001. Ministry of Justice. Annual Report of Statistics on Legal Migrants. Tokyo, Ministry of Justice.

  • 6

    Konishi E, Suzuki T, 2002. Ratios of subclinical to clinical Japanese encephalitis (JE) virus infections in vaccinated populations: evaluation of an inactivated JE vaccine by comparing the ratios with those in unvaccinated populations. Vaccine 21 :98–107.

    • Search Google Scholar
    • Export Citation
  • 7

    Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, Kotchasenee S, Gingrich JB, Latendresse J, Fukai K, Burke DS, 1988. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 319 :608–614.

    • Search Google Scholar
    • Export Citation
  • 8

    Yamada K, Nawa M, Takasaki T, Yabe S, Kurane I, 1999. Laboratory diagnosis of dengue virus infection by reverse transcriptase polymerase chain reaction (RT-PCR) and IgM-capture enzyme-linked immunosorbent assay (ELISA). Jpn J Infect Dis 52 :150–155.

    • Search Google Scholar
    • Export Citation
  • 9

    Yamada K, Takasaki T, Nawa M, Yabe S, Kurane I, 2003. Antibody responses determined for Japanese dengue fever patients by neutralization and hemagglutination inhibition assays demonstrate cross-reactivity between dengue and Japanese encephalitis viruses. Clin Diagn Lab Immunol 10 :725–728.

    • Search Google Scholar
    • Export Citation
  • 10

    Clarke T, 2002. Dengue virus: Break-bone fever. Nature 416 :672–674.

  • 11

    Kalayanarooj S, Vaughn DW, Nimmannitya S, Green S, Suntayakorn S, Kunentrasai N, Viramitrachai W, Ratanachueke S, Kiatpolpoj S, Innis BL, Rothman AL, Nisalak A, Ennis FA, 1997. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 176 :313–321.

    • Search Google Scholar
    • Export Citation
  • 12

    Schwartz E, Mendelson E, Sidi Y, 1996. Dengue fever among travelers. Am J Med 101 :516–520.

  • 13

    Guard RW, Stallman ND, Wiemers MA, 1984. Dengue in the northern region of Queensland, 1981–1982. Med J Aust 140 :765–769.

  • 14

    Infectious Diseases Control Division, Ministry of Health and Welfare, Infectious Disease Surveillance Center, National Institute of Infectious Diseases, 1996. Annual Report 1996. National Epidemiological Surveillance of Vaccine-Preventable Diseases. Tokyo, Ministry of Health and Welfare.

  • 15

    Peragallo MS, Nicoletti L, Lista F, D’Amelio R, East Timor Dengue Study Group, 2003. Probable dengue virus infection among Italian troops, East Timor, 1999–2000. Emerg Infect Dis 9 :876–880.

    • Search Google Scholar
    • Export Citation





View More View Less
  • 1 Department of Infectious Diseases, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan; Department of Infectious Diseases, Tokyo Women’s Medical University, Tokyo Japan; Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan
Restricted access

To describe the clinical features of dengue cases in Japan, a retrospective study was conducted on 62 laboratory-confirmed Japanese dengue cases presented to Tokyo Metropolitan Komagome Hospital between 1985 and 2000. Age distribution was from 18 to 62 years old (mean, 31.5 years). All cases were imported from abroad and diagnosed as dengue fever. Clinical manifestations included fever (100%), headache (90%), and skin rash (82%). Laboratory examinations revealed leukocytopenia (71%), thrombocytopenia (57%), elevated levels of serum aspartate aminotransferase (78%), and lactate dehydrogenase (71%). Antibody responses were consistent with that of secondary flavivirus infection in 60% of cases. Severity of symptoms in patients with primary dengue antibody response and those with secondary flavivirus antibody responses didn’t show statistical significance. Dengue virus infection should be taken into consideration in the differential diagnosis of febrile patients who recently entered Japan from tropical or subtropical countries.